1. Akiyama M, Takeichi T, McGrath JA, Sugiura K. (2017) Autoinflammatory keratinization diseases.
J Allergy Clin Immunol, 140 (6): 1545-1547.
[PMID:28668225]
2. Bleda S, de Haro J. (2018) Identification of a potential inhibitor of NLRP1 inflammasome for the treatment of peripheral arterial disease.
Int J Cardiol, 256: 30.
[PMID:29454411]
3. Bleda S, de Haro J, Varela C, Ferruelo A, Acin F. (2016) Elevated levels of triglycerides and vldl-cholesterol provoke activation of nlrp1 inflammasome in endothelial cells.
Int J Cardiol, 220: 52-5.
[PMID:27372042]
4. Chamaillard M, Girardin SE, Viala J, Philpott DJ. (2003) Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation.
Cell Microbiol, 5 (9): 581-92.
[PMID:12925128]
5. Chavarría-Smith J, Vance RE. (2015) The NLRP1 inflammasomes.
Immunol Rev, 265 (1): 22-34.
[PMID:25879281]
6. Grandemange S, Sanchez E, Louis-Plence P, Tran Mau-Them F, Bessis D, Coubes C, Frouin E, Seyger M, Girard M, Puechberty J et al.. (2017) A new autoinflammatory and autoimmune syndrome associated with NLRP1 mutations: NAIAD (NLRP1-associated autoinflammation with arthritis and dyskeratosis).
Ann Rheum Dis, 76 (7): 1191-1198.
[PMID:27965258]
7. Karki R, Man SM, Kanneganti TD. (2017) Inflammasomes and Cancer.
Cancer Immunol Res, 5 (2): 94-99.
[PMID:28093447]
8. Maver A, Lavtar P, Ristić S, Stopinšek S, Simčič S, Hočevar K, Sepčić J, Drulović J, Pekmezović T, Novaković I et al.. (2017) Identification of rare genetic variation of NLRP1 gene in familial multiple sclerosis.
Sci Rep, 7 (1): 3715.
[PMID:28623311]
9. Pan Y, Wang Y, Xu J, Wu J, Chen Q, Zeng G, Zhao G. (2017) TG and VLDL cholesterol activate NLRP1 inflammasome by Nuclear Factor-κB in endothelial cells.
Int J Cardiol, 234: 103.
[PMID:28062143]
10. Place DE, Kanneganti TD. (2018) Recent advances in inflammasome biology.
Curr Opin Immunol, 50: 32-38.
[PMID:29128729]
11. Saresella M, La Rosa F, Piancone F, Zoppis M, Marventano I, Calabrese E, Rainone V, Nemni R, Mancuso R, Clerici M. (2016) The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease.
Mol Neurodegener, 11: 23.
[PMID:26939933]
12. Sharma N, Jha S. (2016) NLR-regulated pathways in cancer: opportunities and obstacles for therapeutic interventions.
Cell Mol Life Sci, 73 (9): 1741-64.
[PMID:26708292]
13. Sönmez HE, Özen S. (2017) A clinical update on inflammasomopathies.
Int Immunol, 29 (9): 393-400.
[PMID:28387826]
14. Wang W, Wang C, Gong Y, Zhang X. (2018) Inhibition of NLRP1 inflammasome might be a novel therapeutic target in the treatment of peripheral arterial disease.
Int J Cardiol, 256: 29.
[PMID:29454409]
15. Yu CH, Moecking J, Geyer M, Masters SL. (2018) Mechanisms of NLRP1-Mediated Autoinflammatory Disease in Humans and Mice.
J Mol Biol, 430 (2): 142-152.
[PMID:28733143]
16. Zhai Z, Liu W, Kaur M, Luo Y, Domenico J, Samson JM, Shellman YG, Norris DA, Dinarello CA, Spritz RA et al.. (2017) NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma.
Oncogene, 36 (27): 3820-3830.
[PMID:28263976]
17. Zhong FL, Mamaï O, Sborgi L, Boussofara L, Hopkins R, Robinson K, Szeverényi I, Takeichi T, Balaji R, Lau A et al.. (2016) Germline NLRP1 Mutations Cause Skin Inflammatory and Cancer Susceptibility Syndromes via Inflammasome Activation.
Cell, 167 (1): 187-202.e17.
[PMID:27662089]